Show simple item record

dc.contributor.authorDurnwald, Celeste P
dc.contributor.authorMomirova, Valerija
dc.contributor.authorRouse, Dwight J
dc.contributor.authorCaritis, Steve N
dc.contributor.authorPeaceman, Alan M
dc.contributor.authorSciscione, Anthony
dc.contributor.authorVarner, Michael W
dc.contributor.authorMalone, Fergal D
dc.contributor.authorMercer, Brian M
dc.contributor.authorThorp, John M
dc.contributor.authorSorokin, Yoram
dc.contributor.authorCarpenter, Marshall W
dc.contributor.authorLo, Julie
dc.contributor.authorRamin, Susan M
dc.contributor.authorHarper, Margaret
dc.contributor.authorSpong, Catherine Y
dc.date.accessioned2011-11-18T15:08:59Z
dc.date.available2011-11-18T15:08:59Z
dc.date.issued2010-12
dc.identifier.citationSecond trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate. 2010, 23 (12):1360-4 J. Matern. Fetal. Neonatal. Med.en
dc.identifier.issn1476-4954
dc.identifier.pmid20441408
dc.identifier.doi10.3109/14767051003702786
dc.identifier.urihttp://hdl.handle.net/10147/189974
dc.descriptionOBJECTIVE: To compare rates of preterm birth before 35 weeks based on cervical length measurement at 16-20 weeks in women with twin gestations who received 17-α hydroxyprogesterone caproate (17OHPC) or placebo. METHODS: This is a secondary analysis of a randomised, double-blind, placebo-controlled trial of twin gestations exposed to 17OHPC or placebo. Baseline transvaginal ultrasound evaluation of cervical length was performed prior to treatment assignment at 16-20 weeks. Cervical length measurements were categorised according to the 10th, 25th, 50th and 75th percentiles in the women studied. The effect of 17OHPC administration in women with a short (25th percentile) and long (75th percentile) cervix was evaluated. RESULTS: Of 661 twin gestations studied, 221 (33.4%) women enrolled at 11 centers underwent cervical length measurement. The 10th, 25th, 50th, 75th percentiles for cervical length at 16-20 weeks were 32, 36, 40 and 44 mm, respectively. The risk of preterm birth <35 weeks was increased in women with a cervical length <25th percentile (55.8 vs. 36.9%, p=0.02). However, a cervical length >75th percentile at this gestational age interval was not protective for preterm birth (36.5 vs. 42.9%, p=0.42). Administration of 17OHPC did not reduce preterm birth before 35 weeks among those with either a short or a long cervix (64.3 vs. 45.8%, p=0.18 and 38.1 vs. 35.5%, p=0.85, respectively). CONCLUSION: Women with twin gestations and a cervical length below the 25th percentile at 16-20 weeks had higher rates of preterm birth. In this subgroup of women, 17 OHPC did not prevent preterm birth before 35 weeks gestation. A cervical length above the 75th percentile at 16-20 weeks did not significantly reduce the risk of preterm birth in this high risk population.en
dc.description.abstractTo compare rates of preterm birth before 35 weeks based on cervical length measurement at 16-20 weeks in women with twin gestations who received 17-α hydroxyprogesterone caproate (17OHPC) or placebo.
dc.description.abstractThis is a secondary analysis of a randomised, double-blind, placebo-controlled trial of twin gestations exposed to 17OHPC or placebo. Baseline transvaginal ultrasound evaluation of cervical length was performed prior to treatment assignment at 16-20 weeks. Cervical length measurements were categorised according to the 10th, 25th, 50th and 75th percentiles in the women studied. The effect of 17OHPC administration in women with a short (25th percentile) and long (75th percentile) cervix was evaluated.
dc.description.abstractOf 661 twin gestations studied, 221 (33.4%) women enrolled at 11 centers underwent cervical length measurement. The 10th, 25th, 50th, 75th percentiles for cervical length at 16-20 weeks were 32, 36, 40 and 44 mm, respectively. The risk of preterm birth <35 weeks was increased in women with a cervical length <25th percentile (55.8 vs. 36.9%, p=0.02). However, a cervical length >75th percentile at this gestational age interval was not protective for preterm birth (36.5 vs. 42.9%, p=0.42). Administration of 17OHPC did not reduce preterm birth before 35 weeks among those with either a short or a long cervix (64.3 vs. 45.8%, p=0.18 and 38.1 vs. 35.5%, p=0.85, respectively).
dc.description.abstractWomen with twin gestations and a cervical length below the 25th percentile at 16-20 weeks had higher rates of preterm birth. In this subgroup of women, 17 OHPC did not prevent preterm birth before 35 weeks gestation. A cervical length above the 75th percentile at 16-20 weeks did not significantly reduce the risk of preterm birth in this high risk population.
dc.language.isoenen
dc.relation.urlhttp://informahealthcare.com/doi/abs/10.3109/14767051003702786en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999406/pdf/nihms253511.pdfen
dc.subject.meshAdult
dc.subject.meshCervix Uteri
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshGestational Age
dc.subject.meshHumans
dc.subject.meshHydroxyprogesterones
dc.subject.meshPlacebos
dc.subject.meshPregnancy
dc.subject.meshPregnancy Trimester, Second
dc.subject.meshPremature Birth
dc.subject.meshRisk Factors
dc.subject.meshTwins
dc.titleSecond trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate.en
dc.typeArticleen
dc.contributor.departmentDepartment of Obstetrics and Gynecology, The Ohio State University, Columbus, OH 43210, USA. celeste.durnwald@osumc.eduen
dc.identifier.journalThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetriciansen
dc.description.provinceLeinster
html.description.abstractTo compare rates of preterm birth before 35 weeks based on cervical length measurement at 16-20 weeks in women with twin gestations who received 17-α hydroxyprogesterone caproate (17OHPC) or placebo.
html.description.abstractThis is a secondary analysis of a randomised, double-blind, placebo-controlled trial of twin gestations exposed to 17OHPC or placebo. Baseline transvaginal ultrasound evaluation of cervical length was performed prior to treatment assignment at 16-20 weeks. Cervical length measurements were categorised according to the 10th, 25th, 50th and 75th percentiles in the women studied. The effect of 17OHPC administration in women with a short (25th percentile) and long (75th percentile) cervix was evaluated.
html.description.abstractOf 661 twin gestations studied, 221 (33.4%) women enrolled at 11 centers underwent cervical length measurement. The 10th, 25th, 50th, 75th percentiles for cervical length at 16-20 weeks were 32, 36, 40 and 44 mm, respectively. The risk of preterm birth <35 weeks was increased in women with a cervical length <25th percentile (55.8 vs. 36.9%, p=0.02). However, a cervical length >75th percentile at this gestational age interval was not protective for preterm birth (36.5 vs. 42.9%, p=0.42). Administration of 17OHPC did not reduce preterm birth before 35 weeks among those with either a short or a long cervix (64.3 vs. 45.8%, p=0.18 and 38.1 vs. 35.5%, p=0.85, respectively).
html.description.abstractWomen with twin gestations and a cervical length below the 25th percentile at 16-20 weeks had higher rates of preterm birth. In this subgroup of women, 17 OHPC did not prevent preterm birth before 35 weeks gestation. A cervical length above the 75th percentile at 16-20 weeks did not significantly reduce the risk of preterm birth in this high risk population.


This item appears in the following Collection(s)

Show simple item record